Table 1.
Baseline Clinical Characteristics for Unscreened and Screened Cohorts
| Variablea,b | Unscreened Cohort (n=2,246) |
Screened Cohort (n=292) |
P Value |
|---|---|---|---|
| Age at diabetes diagnosis, y | 54.7 (14.1) | 55.5 (10.7) | .31 |
| Male sex | 1,170 (52.1) | 188 (64.4) | <.001 |
| Body mass index, kg/m2 | 33.5 (7.5) | 34.4 (7.5) | .11 |
| Diabetes mellitus type | .01 | ||
| 1 | 76 (3.4) | 2 (0.7) | |
| 2 | 2,157 (96.6) | 285 (99.3) | |
| Diabetes treatment | .01 | ||
| Diet | 1,170 (53.5) | 178 (62.9) | |
| Oral medication | 786 (35.9) | 81 (28.6) | |
| Insulin | 232 (10.6) | 24 (8.5) | |
| Family history of CAD | 151 (6.8) | 34 (11.9) | .002 |
| Hypertension | 1,083 (49.0) | 154 (53.8) | .13 |
| Peripheral arterial disease | 41 (1.9) | 8 (2.8) | .28 |
| Current smoking | 319 (14.5) | 50 (17.5) | .17 |
| Statin use | 486 (22.6) | 71 (25.5) | .26 |
| Aspirin use | 524 (24.0) | 93 (32.9) | .001 |
| ACE-I or ARB use | 504 (24.1) | 68 (24.8) | .79 |
| β-Blocker use | 306 (18.0) | 51 (20.5) | .35 |
| Systolic BP, mm Hg | 136 (19) | 136 (18) | .62 |
| Diastolic BP, mm Hg | 79 (12) | 80 (11) | .25 |
| HDL-C, mg/dL | 44 (13) | 42 (12) | .01 |
| LDL-C, mg/dL | 120 (37) | 125 (40) | .06 |
| Total cholesterol, mg/dL | 212 (51) | 218 (69) | .06 |
| Triglycerides, mg/dL | 244 (212) | 272 (338) | .07 |
| Framingham Risk Scorec | 14.5 (9.5) | 16.7 (9.2) | <.001 |
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
a
Data are presented as number and percentage of patients for categorical and as mean (SD) for continuous variables.
b
Laboratory data were 71% complete; BP data, 81% complete; and comorbidity data, 98% complete.
c
Ten-year risk estimate of CAD.